Issue #16 — The Medication Shortage Is Your Business Continuity Problem
🎯 TL;DR
The 2022–2026 ADHD stimulant shortage isn't a personal inconvenience — it's an unmodelled operational risk inside your company. If your executive function depends on a regulated Schedule II supply chain, you need a continuity plan, not a coping strategy.
This week: Why the stimulant shortage is a founder issue, and the BCP framework that treats it like one.
Read time: 6 minutes
💊 The Pharmacy Counter Moment
You stand at the CVS counter. The tech says "we're out, and we don't know when." You drove 22 miles. You check GoodRx. You text your prescriber. You feel that familiar crawl up your spine — half panic, half shame, the specific cocktail your nervous system reserves for the system is failing me and somehow it's my fault.
Now reframe. You're not a patient at a pharmacy. You're a CEO whose primary input — the chemical that lets your cortex prioritise, sequence, and ship — just experienced a stockout. Your only supplier is the federal government (which sets the annual production quota), plus a handful of generics manufacturers fighting over the same API. Your customer (you) just absorbed a Sev-1 incident. Where's your runbook?
Most founders don't have one. We treat this like personal failure when it's a business continuity problem with a four-year-and-counting public paper trail.
🔬 What's Actually Going On
The AJMC piece "US ADHD Stimulant Shortage Highlights Growing Challenges in Adult Treatment" (April 26, 2026) reports that more than 70% of adults on ADHD medication had difficulty filling at least one prescription during the shortage's recent peak. The FDA first declared Adderall in shortage in October 2022. That declaration is now in its fourth year. Vyvanse generics, which launched in 2023, hit their own supply walls. Concerta, methylphenidate, and lisdexamfetamine have all rotated through the FDA's shortage list since.
A Yale-led analysis in JAMA Health Forum (March 2026) traced the bottleneck and found something inconvenient for the dominant narrative: the shortage is not driven by adult over-prescribing or "TikTok diagnoses." It's a stack of supply chain failures — DEA aggregate production quotas set without manufacturer-by-manufacturer transparency, single-source API suppliers concentrated in a few countries, and Teva (the largest US generic Adderall manufacturer) trimming capacity in 2022 without a coordinated handoff. Demand did rise — adult ADHD diagnoses roughly doubled between 2020 and 2023 — but supply contracted at the same time. That's a supply chain failure, not a patient failure.
"Patients are being asked to absorb the cost of a regulatory and manufacturing failure they have no power to influence." — paraphrased from the Yale/JAMA Health Forum authors, March 2026
Here's what the dominant story gets wrong, side by side:
| What people think | What's actually happening |
|---|---|
| Too many adults are getting diagnosed | Diagnosis rates are rising but remain below prevalence estimates |
| Doctors are over-prescribing | DEA quotas cap total supply regardless of clinical demand |
| It's a TikTok problem | API supply, manufacturer exits, and quota lag are upstream of any patient |
| Patients should "just try non-stim" | Non-stimulants work for ~50% of responders; many founders aren't responders |
| The shortage will resolve soon | It has been ongoing since October 2022 with no structural fix |
If you ran a SaaS company whose only API provider had been "intermittently down" since October 2022, you would have migrated, dual-sourced, or built fallbacks 36 months ago. You would not still be hoping next quarter is better.
🛠️ A Founder's Stimulant Continuity Plan
Build it the way you'd build any BCP. Five steps.
-
Map the supply chain. List every pharmacy within driving distance. Note which chains share inventory systems (CVS and Walgreens don't; Costco often has stock when chains don't, and you don't need a membership for the pharmacy counter). Use GoodRx and Cost Plus lookups. Write down your prescriber's policy on transferring Schedule II scripts. Put it in a Notion doc titled "Meds Ops" — treat it like vendor management.
-
Establish a refill ritual on day 21, not day 28. Schedule II prescriptions can't be refilled early in most states, but you can request the new prescription early so the pharmacy can begin sourcing. Set a recurring 15-minute calendar block — "Meds Ops" — for the third Monday of every month. This kills the surprise scramble that always lands on a Friday afternoon.
-
Build an evidence-based non-med fallback stack. Not as replacement — as buffer. The literature supports: 30+ minutes of zone-2 cardio (Ratey, Spark; meta-analyses in Translational Psychiatry 2023), a protein-forward breakfast (supports dopamine precursors and delays the glucose crash), 100–200mg caffeine paired with L-theanine, 10 minutes of bright outdoor light within 60 minutes of waking, and a hard cut on alcohol during low-med weeks. Stacked, these recover maybe 30–50% of your baseline executive function — enough to ship reduced scope without eating your lunch.
-
Write the Low-Med Protocol. A one-page doc answering: which tasks do I protect, which do I defer, which do I delegate? On low-med days, you protect the single revenue-driving deep work block, defer admin and inbox triage, and postpone ambiguous strategy work. Decide this once, while medicated, so you're not deciding it on a bad day.
-
Stockpile only what's legal. You can't legally stockpile Schedule II. You can keep a 30-day buffer of every non-stimulant tool — caffeine, electrolytes, prepped freezer meals, blank pharmacy transfer forms, and a ready-to-send template to your prescriber. Stockpile the scaffolding around the molecule.
Then advocate. Email your representatives about DEA quota transparency. Sign onto ADDA's policy efforts. Founders are unusually well-positioned to make noise about supply chain failures because we already speak that language fluently.
⚡ The ADHD Angle
Stimulants for many of us aren't "treatment" in the polite-medical sense. They are the executive function infrastructure that lets the rest of the cognitive stack run. When that infrastructure fails, the ADHD brain doesn't gracefully degrade — it triggers RSD, freezes on prioritisation, and burns dopamine on the meta-task of managing the shortage itself. You spend three hours calling pharmacies and call it a "lost morning," but the actual cost is closer to two days because your nervous system is now keyed up about the next refill too.
That's why the BCP framing matters. Reframing the shortage from "personal medical issue" to "operational risk" unlocks the parts of your brain that are already good at this — the founder pattern-matching that handles vendor lock-in, single points of failure, and supplier concentration. You stop feeling ashamed of needing a continuity plan and start feeling competent for having one. That shift alone protects more executive function than any single non-stim intervention on the list above.
🎯 This Week's Challenge
- Build your Meds Ops doc (20 minutes). List every pharmacy within 15 miles, your prescriber's transfer policy, and your day-21 refill date. Pin it in Notion next to your vendor list.
- Write your one-page Low-Med Protocol. What you protect, defer, and delegate when the bottle's empty. Decide it now, while you can think clearly — not at the pharmacy counter.
- Send one advocacy email. To your senator, to ADDA, or to your prescriber's practice asking what their shortage protocol looks like. Thirty minutes total. Founders who don't make noise about supply chains lose them.
See you Tuesday, L-P
P.S. — If this resonated, forward it to one ADHD founder who's been white-knuckling refills in private. The shame compounds in silence. Continuity plans compound in the open.
Divergent — Strategy for brains that don't do boring.